Oral, inactivated, whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine: Results of the initial evaluation in children

Journal of Infectious Diseases

Volumn 179, Issue 1, 1999, Pages 107-114

  Savarino, Stephen J ^c   Hall, Eric R ^a   Bassily, Samir ^c   Brown, F Matthew ^b   Youssef, Fouad ^c   Wierzba, Thomas F ^c   Peruski, Leonard ^c   El Masry, Nabil A ^c   Safwat, Mohammed ^c   Rao, Malla ^c   El Mohamady, Hanan ^c   Abu Elyazeed, Remon ^c   Naficy, Abdollah ^c   Svennerholm, Ann Mari ^c   Jertborn, Marianne ^c   Lee, Young J ^c   Clemens, John D ^c  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b Hickory Acute Care Specialists   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIN; BACTERIAL VACCINE; CHOLERA TOXIN B SUBUNIT; COLI SURFACE ANTIGEN 2; COLI SURFACE ANTIGEN 4; COLONIZATION FACTOR ANTIGEN I; ESCHERICHIA COLI ENTEROTOXIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ANOREXIA; ANTIBODY PRODUCTION; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; EGYPT; ENTEROBACTER INFECTION; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION; VOMITING;

ADMINISTRATION, ORAL; AGE FACTORS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CHILD; CHILD, PRESCHOOL; CHOLERA TOXIN; COHORT STUDIES; DOUBLE-BLIND METHOD; EGYPT; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI VACCINES; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; SAFETY; TIME FACTORS; VACCINES, CONJUGATE; VACCINES, INACTIVATED;

EID: 0343588428     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314543     Document Type: Article

References (38)

1. Bishop RF, Davidson GP, Holmes IH, Ruck BJ. Detection of a new virus by electron microscopy of fecal extracts from children with acute gastroenteritis. Lancet 1974;1:149-51.
2. DuPont HL, Formal SB, Hornick RB, et al. Pathogenesis of Escherichia coli diarrhea. N Engl J Med 1971;285:1-9.
3. Rennels MB, Glass RI, Dennehy PH, et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - report of the National Multicenter Trial. Pediatrics 1996;97:7-13.
4. Institute of Medicine. The prospects for immunizing against Escherichia coli. In: New vaccine development: establishing priorities. Vol 2. Washington, DC: National Academy Press, 1986:178-85.
5. Black RE, Merson MH, Huq I, Alim ARMA, Yunus M. Incidence and severity of rotavirus and Escherichia coli diarrhoea in rural Bangladesh: implications for vaccine development. Lancet 1981;1:141-3.
6. Gaastra W, Svennerholm AM. Colonization factors of human enterotoxigenic Escherichia coli (ETEC). Trends Microbiol 1996;4:444-52.
7. Evans DG, Evans DJJ, Tjoa WS, DuPont HL. Detection and characterization of colonization factor of enterotoxigenic Escherichia coli isolated from adults with diarrhea. Infect Imunun 1978;19:727-36.
8. Binsztein N, Jouve MJ, Viboud GI, et al. Colonization factors of enterotoxigenic Escherichia coli in children with diarrhea in Argentina. J Clin Microbiol 1991;29:1893-8.
9. Wolf MK, Taylor DN, Boedeker EC, et al. Characterization of enterotoxigenic Escherichia coli isolated from U.S. troops deployed to the Middle East. J Clin Microbiol 1993;31:851-6.
10. Cravioto A, Scotland SM, Rowe B. Hemagglutination activity and colonization factor antigens I and II in enterotoxigenic and non enterotoxigenic Escherichia coli isolated from humans. Infect Immun 1982;36:189-97.
11. Smyth CJ. Serologically distinct fimbriae on enterotoxigenic Escherichia coli of serotype 06:K15:H16 or H-. FEMS Microbiol Lett 1984;21:51-7.
12. Thomas LV, Cravioto A, Scotland SM, Rowe B. New fimbrial antigenic type (E8775) that may represent a colonization factor in enterotoxigenic Escherichia coli in humans. Infect Immun 1982;35:1119-24.
13. Clemens JD, Sack DA, Harris JR, et al. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli results of a large-scale field trial. J Infect Dis 1988;158:372-7.
14. Levine MM, Black RE, Clements ML, Nalin DR, Cisneros L, Finkelstein RA. Volunteer studies in development of vaccines against cholera and enterotoxigenic Escherichia coli: a review. In: Holme T, Holmgren J, Merson MH, Mollby R, eds. Acute enteric infections in children. Amsterdam: Elsevier/North-Holland Biomedical Press, 1981:443-59.
15. Svennerholm AM, Holmgren J, Sack DA. Development of oral vaccines against enterotoxigenic Escherichia coli diarrhoea. Vaccine 1989;7:196-8.
16. Czerkinsky C, Svennerholm AM, Holmgren J. Induction and assessment of immunity at enteromucosal surfaces in humans: implications for vaccine development. Clin Infect Dis 1993;16(suppl 2):S106-16.
17. Ahren CM, Svennerholm AML. Synergistic protective effect of antibodies against Escherichia coli enterotoxin and colonization factor antigens. Infect Immun 1982;38:74-9.
18. Peltola H, Siitonen A, Kyronseppa H, et al. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet 1991;338:1285-9.
19. Svennerholm AM, Ahren C, Jertborn M. Oral inactivated vaccines against enterotoxigenic Escherichia coli. In: Levine MM, Woodrow GC, Kaper JB, Gabon GS, eds. New generation vaccines. 2nd ed. New York: Marcel Dekker, 1997:865-74.
20. Jertborn M, Ahren C, Holmgren J, Svennerholm AM. Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli vaccine. Vaccine 1998;16:255-60.
21. Zaki AM, Dupont HL, El Alamy MA, et al. The detection of enteropathogens in acute diarrhea in a family cohort population in rural Egypt. Am J Trop Med Hyg 1986;35:1013-22.
22. Savarino SJ, Brown FM, Hall E, et al. Safety and immunogenicity of an oral, killed enterotoxigenic Escherichia coli cholera toxin B subunit vaccine in Egyptian adults. J Infect Dis 1998;177:796-9.
23. Ahren C, Wenneras C, Holmgren J, Svennerholm AM. Intestinal antibody response after oral immunization with a prototype cholera B subunit-colonization factor antigen enterotoxigenic Escherichia coli vaccine. Vaccine 1993;11:929-34.
24. Wenneras C, Svennerholm AM, Ahren C, Czerkinsky C. Antibody-secreting cells in human peripheral blood after oral immunization with an inactivated enterotoxigenic Escherichia coli vaccine. Infect Immun 1992;60:2605-11.
25. Clemens JD, Stanton BF, Chakraborty J, et al. B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity. J Infect Dis 1987;155:79-85.
26. Czerkinsky C, Nilsson LA, Nygren H, Ouchterlony O, Tarkowski A. A solidphase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 1983;65:109-21.
27. Svennerholm AM, Holmgren J, Black R, Levine MM, Merson MM. Serologic differentiation between antitoxin responses to infection with Vibrio cholerae and enterotoxin-producing Escherichia coli. J Infect Dis 1983;147:514-22.
28. Jertborn M, Svennerholm AM, Holmgren J. Saliva, breast milk, and serum antibody responses as indirect measure of intestinal immunity after cholera vaccination and natural disease. J Clin Microbiol 1986;24:203-9.
29. 1-ELISA) procedure. Curr Microbiol 1978;1:19-23.
30. 1 enzyme-linked immunosorbent assay. J Clin Microbiol 1990;28:2175-7.
31. Lopez-Vidal Y, Svennerholm AM. Monoclonal antibodies against the different subcomponents of colonization factor antigen II of enterotoxigenic Escherichia coli. J Clin Microbiol 1990;28:1906-12.
32. Viboud GL, Binsztein N, Svennerholm AM. Characterization of monoclonal antibodies against putative colonization factors of enterotoxigenic Escherichia coli and their use in an epidemiological study. J Clin Microbiol 1993;31:558-64.
33. Blackwelder WC. "Proving the null hypothesis" in clinical trials. Controlled Clin Trials 1982;3:345-53.
34. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998;17:873-90.
35. Mehta C, Patel N. StatXact-Turbo: statistical software for exact nonparametric inference user manual. Cambridge, MA: Cytel Software, 1992.
36. Sanchez JL, Trofa AF, Taylor DN, et al. Safety and immunogenicity of the oral, whole cell/recombinant B subunit cholera vaccine in North American volunteers. J Infect Dis 1993;167:1446-9.
37. Ing DJ, Glass RI, Woods PA, et al. Immunogenicity of tetravalent rhesus rotavirus vaccine administered with buffer and oral polio vaccine. Am J Dis Child 1991;145:892-7.
38. Ahren C, Jertborn M, Svennerholm AM. Intestinal immune responses to an inactivated oral enterotoxigenic Escherichia coli vaccine and associated immunoglobulin A responses in blood. Infect Immun 1998;66:3311-6.